THERAPY DOSSIER · th-ee853720a38a

Glucagon-like peptide-1 (GLP-1)

Hormone

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Fracture
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02333591 ↗PHASE4completed

Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

Coronary Microvascular Dysfunction

Enrolment: 25 · Results not recorded

NCT02591849 ↗NAcompleted

GLP-1 Restores Altered Insulin and Glucagon Secretion in Post-transplantation Diabetes Mellitus

Post-transplant Diabetes Mellitus

Enrolment: 24 · Results not recorded

NCT01333163 ↗NAcompleted

GLP-1: Acute Effects on Kidney Function in Healthy Men

Kidney Functional

Enrolment: 12 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30811247 ↗2019Reported benefit

Early treatment with GLP-1 after severe trauma preserves renal function in obese Zucker rats.

RatFractureUnspecifiedObese ZuckerContinuous intravenous infusion3 micrograms/kg/h, 1.5 mL/kg total volumeFrom 30 min to 5 h after trauma

Model: Bilateral hindlimb soft tissue injury, fibula fracture and homogenised bone component injection (severe extremity trauma)

GLP-1 infusion significantly attenuated early post-traumatic hyperglycaemia, reduced the trauma-induced rise in plasma IL-6 at 1 day, and normalised renal blood flow, glomerular filtration rate and renal oxygen delivery without altering renal oxygen consumption.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…